Jefferies on Praxis Precision Medicines Inc. (PRAX): 'see 5%+ stock upside as FDA accepts the NDA for ulixacaltamide'

April 14, 2026 11:38 AM

Jefferies analyst Andrew Tsai reiterated a Buy rating and $525.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found